Ethics, Business, Innovation Andreas Loefler Adrian Cosenza Australia.

Slides:



Advertisements
Similar presentations
The Role of Government in Encouraging a High Standard of Ethics in the Healthcare Sector: Indonesia Experience Prof. Agus Purwadianto Senior Adviser to.
Advertisements

Ethics review and oversight for better governance of health research Amar Jesani Indian Journal of Medical Ethics Centre for Studies in Ethics and Rights.
Building an EU consensus for minimum quality standards in the prevention, treatment and harm reduction of drugs Quality Standards - Policy Perspectives.
The Israel Export & International Cooperation Institute Israel’s Medical Devices and Supplies Industry Rising to the Challenge.
The Changing Regulatory Environment for Industry Support The accreditation bodies’ point of view. Ian Starke (UK)
1 The Development of Corporate Governance in Hong Kong Paul M Y Chow Chief Executive Hong Kong Exchanges and Clearing Limited Presented at the AIA Luncheon,
CPME Comité Permanent des Médecins Européens Standing Committee of European Doctors Doctors and industry - European perspective International.
Ethical Issues in Patent Law Biotechnology and Research Ethics Clinical Research: Conflicts and Controversies Patricia C. Kuszler, M.D., J.D. University.
The organizational form of Social Enterprise in UK: practice and enlightenment 1 Ellen Li 5 FEB
Year 11 R and S Ethics Great Ethical Thinkers. Codes of Ethics in Society.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Introducing New Techniques and New Technologies: Role of the BOA Code of Ethics Gordon Bannister Professor of Orthopaedic Surgery University of Bristol.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
Medical Research BADRAG meeting Jan 2013 Dr H Sari-Kouzel.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
THE ORTHOPAEDIC SURGEON’S RELATIONSHIPS WITH INDUSTRY AAOS ETHICS COMMITTEE Kenneth C. Thomas, MD 1.
Introductory training Medical Technology Industry Code of Practice.
Yesterday, today, and tomorrow
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
INTRODUCTION TO RA.
Business Organisation & Environment Stakeholders 1.
Health Insurance Portability and Accountability Act (HIPAA)
Disruptive versus incremental innovation in healthcare … twitter/medicalfutures Andy Goldberg MD FRCS(Tr&Orth) Consultant Orthopaedic Surgeon Royal National.
Patient Safety Friendly Hospital Intiative Purpose Implementation of a set of patient safety standards in hospitals Implementation of a set of patient.
Legal, Regulatory, and Political Issues
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
“Delivering Therapeutic Agents” - Marketing and Communication Strategies of Drug Companies Safura Nantogmah.
Security of the Distributed Electronic Patient Record: A Case-Based Approach James G. Anderson, Ph.D. Purdue University.
THE FIRST INTERNATIONAL MEDICAL DEVICE COMPLIANCE CONGRESS May , 2008 Paris Marriott Rive Gauche Hotel and Conference Center Paris, France Joachim.
Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Role of Regulation in Optimizing Medicine use KNH/UON Pharmacy Symposium Optimizing Medicine.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
Ethics.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
+ Role of Industry in Clinical Care, Research, and Education.
Managing Conflicts of Interest at the IRB and Institutional Level: INSTITUTIONAL CONFLICTS OF INTEREST Claudia R. Adkison, J.D., Ph.D. Executive Associate.
Conflict of Interest in Human Subjects Research Bette-Jane Crigger, PhD.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Agenda for Session Compliance in Clinical Research
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
Lilly Answers that Matter. Preserving the Value of Industry Interactions with Health Care Professionals Jack Harris, M.D. Vice President, U.S. Medical.
4th OECD Asian Roundtable on Corporate Governance: Promoting Shareholder Participation Vincent Duhamel State Street Global Advisors November 2002.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Business Ethics Learning outcome: Understand the meaning and importance of ethics in the business world P1.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
8 th November 2007 Research: ethics and research governance Rossana Dowsett Research and Regional Development Division [Pre Award Support] University of.
Using Australian Clinical Sites – Challenges for International Sponsors Prof A J (Tony) Webber Clinical Network Services Pty Ltd Brisbane, Australia.
F Designed to give you knowledge and application of: Section A: Business organisational structure, governance & management A1. The business organisation.
Risk Management in the National Health Service in England Stuart Emslie Head of Controls Assurance Department of Health, England ISO General Assembly 2001,
Private hospitals association INNOVATIONS IN AN INDUSTRY GUIDED BY ETHICS JOSEPHINE MWAKUTUYA REGISTRAR MEDICAL AND DENTAL PRACTITIONERS OF ZIMBABWE B.
DMC Research Compliance Our mission is to assure that all research at the DMC is ethical, safe and compliant with regulatory standards; and to support.
 The Work of Civil Society in the Field of HIV Prevention Brussels, 23 February 2011 The Work of European AIDS Treatment Group (EATG) 1.
GCP (GOOD CLINICAL PRACTISE)
Medical Device Compliance Congress: Global Device Codes Roundtable - Australia Anne Trimmer.
Current Legal and Ethical Controversies in American Health Care
Clinical Review Process for New Drug Development and Application
Disclosure UK Talking about Transparency.

How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
LSGL ANTI-CORRUPTION COMPLIANCE CONTROL IN COMPANY
Bozeman Health Clinical Research
Disclosure UK Talking about Transparency.
Lilly Grant Funding Disclosure May 27, 2008
Generic Medical Device Company (“MDC”)
Kaisa Immonen EPF Director of Policy
Industry Induction Course
Research, Experimentation, & Clinical Trials
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Surgical safety checklist trial
Presentation transcript:

Ethics, Business, Innovation Andreas Loefler Adrian Cosenza Australia

Collective Aims Promote innovation – New drugs – New devices

Collective Aims Promote innovation – New drugs – New devices Patient safety – Provide a benefit – Do no harm

Collective Aims Promote innovation – New drugs – New devices Patient safety – Provide a benefit – Do no harm Keep the trust – of patients – of community

Specific Objectives Companies – Need profits – Answerable to shareholders – Need clinical outcomes – Need doctors to prescribe

Specific Objectives Companies – Need profits – Answerable to shareholders – Need clinical outcomes – Need doctors to prescribe Doctors – Need patients – Want good outcomes

Specific Objectives Companies – Need profits – Answerable to shareholders – Need clinical outcomes – Need doctors to prescribe Doctors – Need patients – Want good outcomes – Want good incomes

Specific Objectives Governments – Provide health care – Encourage business – Regulate industry Safety Transparency – Control costs

Company Perspective New product Needs safety – Preclinical testing – Regulatory approval

Company Perspective New product Needs safety – Preclinical testing – Regulatory approval – Clinical trials – Clinical papers

Company Perspective New product Needs safety – Preclinical testing – Regulatory approval – Clinical trials – Clinical papers Need sales

Company Perspective New product Needs safety – Preclinical testing – Regulatory approval – Clinical trials – Clinical papers Need sales Target doctors

Doctors’ Perspective Well trained and skeptical Treat patients Enjoy trust in the community Believes in the New

Doctors’ Perspective Well trained and skeptical Treat patients Enjoy trust in the community Believes in the New (Techno Optimism)

Doctors’ Perspective Well trained and skeptical Treat patients Enjoy trust in the community Believes in the New (Techno Optimism) – Better – Quicker – Safer

Doctors’ Perspective Well trained and skeptical Treat patients Enjoy trust in the community Believes in the New (Techno Optimism) – Better – Quicker – Safer – But unproven

Incentives Direct payments Royalties and consultancies Educational support Overseas trips Wining and dining Tickets to rugby games

Three Parties Unusual business model – Company markets the product – Doctors choose the product – Governments pay for the product

Three Parties Unusual business model – Company markets the product – Doctors choose the product – Governments pay for the product Educated players – Sophisticated industry – Highly trained doctors – Specialized government departments

Ethical Problems Drugs or devices untested Informed consent with hope Payments undisclosed Cost of the New is usually high Advertisements overstated

Ethical Problems Drugs or devices untested Informed consent with hope Payments undisclosed Cost of the New is usually high Advertisements overstated Lack Science Use Testimonials

Better Way Company approaches institution No direct payments to doctors Randomized Controlled Trial Minimum 2 year follow up Independent assessment Peer reviewed publication

Registries AOA National Joint Replacement Registry – Captures all hip and knee replacements – Cooperation of surgeons, hospitals, industry – Government funded – Surgeon owned – Post market surveillance – Long term outcomes

Registries Other registries – Anterior Cruciate Ligament – Cardiac stents – Breast implants, etc.

Codes of Conduct Australian Orthopaedic Association – Position Statement on Interaction with Medical Industry Royal Australasian College of Surgeons Australian Medical Association Medical Board of Australia Medical Technology Association Australia State and National Legislation

Interaction with Industry AOA Position Statement spells out – To act in the patients best interest – To avoid commercial persuasion – To disclose financial interests – To acknowledge sponsorship – To refuse gifts

Interaction with Industry MTAA Code stipulates – What companies can and cannot do – How to interact with surgeons AOA requires MTAA compliance Regular discussion and cooperation Arms length funding of projects

Legislation Illegal under Medical Board – To create unrealistic expectation – To use testimonials Corporations Act – Directors to act honestly Crimes Act – Offence to bribe a public official

Legislation Illegal under Medical Board – To create unrealistic expectation – To use testimonials Corporations Act – Directors to act honestly Crimes Act – Offence to bribe a public official (The Brown Paper Bag)

International Code Global trade – Same pathology – Converging medical practice Companies – Multinationals have legal departments – Smaller companies need help Governments – Lobby for business

International Code Global trade – Same pathology – Converging medical practice Companies – Multinationals have legal departments – Smaller companies need help Governments – Lobby for business – Lobby for patients and for ethical practice

Thank you.